Stephan Finical
Charlotte, NCNPI 1740364819
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (56.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 99.7% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $53,987 and has fallen 94.5% since, to $2,958 in 2025.
Across 298 payments — averaging $659.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$196K
- Davol Inc.$179
- Musculoskeletal Transplant Foundation Inc.$118
- Motiva USA, LLC$62
- Mentor Worldwide LLC$38
- TELA Bio, Inc.$38
- plus $74 from 3 others
What the payments were for
- Consulting fees$66,09134%
- Speaking & faculty fees$111,23657%
- Travel & lodging$11,3776%
- Food & beverage$7,6134%
- Education$1010%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 286 | $195,911 |
| Davol Inc. | 2 | $179 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $118 |
| Motiva USA, LLC | 2 | $62 |
| Mentor Worldwide LLC | 1 | $38 |
| TELA Bio, Inc. | 2 | $38 |
| Galderma Laboratories, L.p. | 2 | $35 |
| Revance Therapeutics, Inc. | 1 | $26 |
| Merz North America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NATRELLE SALINE-FILLED BREAST IMPLANTS$47,908
- NATRELLE$19,016
- REVOLVE$16,496
- BOTOX COSMETIC$9,882
- BOTOX$6,282
- ALLODERM$1,313
- ARISTA AH FLEXITIP$141
- KYBELLA$125
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 20 | $155 |
| Cephalexin | 33 | $75 |
| Ondansetron Hcl | 21 | $64 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.